Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Cranston RD, Cespedes MS, Paczuski P, et al. "High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298." Sex Transm Dis. 2018;45(4):266-271.
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Wilkin T, Lee JY, Lensing SY, et al. "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine." HIV Clin Trials. 2013;14(2):75-9.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Shah, iv S, Mildvan D. "HIV and aging." Curr Infect Dis Rep. 2006;8(3):241-7.
Robertson KR, Jiang H, Kumwenda J, et al. "HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings." Clin. Infect. Dis.. 2018.
Yonkers NL, Rodriguez B, Post AB, et al. "HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells." J. Infect. Dis.. 2006;194(3):391-400.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Bronke C, Almeida C-AM, McKinnon E, et al. "HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes." AIDS. 2013;27(6):899-905.
Simpson DM, Kitch D, Evans SR, et al. "HIV neuropathy natural history cohort study: assessment measures and risk factors." Neurology. 2006;66(11):1679-87.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Opollo VS, Wu X, Hughes MD, et al. "HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries." Int. J. Tuberc. Lung Dis.. 2018;22(12):1443-1449.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Robertson K, Oladeji B, Jiang H, et al. "HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction." Clin. Infect. Dis.. 2018.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.
Rockwood N, Meintjes G, Chirehwa M, et al. "HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients." Antimicrob. Agents Chemother.. 2016;60(10):6050-9.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Mitsuya Y, Winters MA, W Fessel J, et al. "HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL." J. Acquir. Immune Defic. Syndr.. 2006;43(1):56-9.
D Salantes B, Zheng Y, Mampe F, et al. "HIV-1 latent reservoir size and diversity are stable following brief treatment interruption." J. Clin. Invest.. 2018;128(7):3102-3115.
Rhee S-Y, Kantor R, Katzenstein DA, et al. "HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes." AIDS. 2006;20(5):643-51.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Sharaf R, Lee GQ, Sun X, et al. "HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers." J. Clin. Invest.. 2018;128(9):4074-4085.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Imamichi H, Degray G, Asmuth DM, et al. "HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy." AIDS. 2011;25(2):159-64.
Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. "HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy." J Womens Health (Larchmt). 2018;27(9):1162-1169.